Data Readout Positive from Trial of New Schizophrenia Drug
Source: Jason Kolbert (06/04/2025)
This new dopamine-serotonin system modulator showed sustained efficacy over 52 weeks and a favorable tolerability and safety profile, noted a D. Boral Capital report.
read more >
Biotech Firm Gains Exclusive Alzheimer's Rights in U.S. and Canada
Source: Streetwise Reports (05/30/2025)
Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) secures exclusive Alzheimer's clinic rights in Canada and key U.S. cities, positioning for a high-growth breakthrough. Learn how Algernon plans to launch cutting-edge clinics featuring PET scan technology and expand into a multibillion-dollar diagnostics market
read more >
A Health Sciences Stock Positioned To Break Out of a Giant Base Pattern
Source: Clive Maund (05/27/2025)
Technical Analyst Clive Maund explains why he thinks PreveCeutical Medical Inc. (PREV:CSE; PRVCF:OTCMKTS) is ready to break out and is rated a Strong Buy.
read more >
Co. Poised to Begin Major New Bull Market
Source: Clive Maund (05/23/2025)
Technical Analyst Clive Maund explains why he thinks Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) is an Immediate Strong Buy.
read more >
Co. Prepares to Roll Out Wound Irrigating Solution
Source: Richard Ryan (05/21/2025)
BioLargo Inc.'s (BLGO:OTCQX) subsidiary has all the necessary partners in place and working on integrating the various systems, such as purchasing, accounting, forecasting, logistics and quality assurance, noted an Oak Ridge Financial report.
read more >